Drug Trial Radar · NCT05972473
A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD
Last checked: Nov 19, 2026Latest source record: Mar 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
600
Actual
Start
Sep 21, 2023
Primary completion
Feb 28, 2027
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is designed for multi-center,randomized,double-masked,active-contralled study to evaluate effective and security of intravitreal injection of IBI302 in subjects with neovascular age-related macular degeneration.
Conditions
- Neovascular Age-related Macular Degeneration
Interventions
Aflibercept OphthalmicDrug
2mg Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive monthes, folloesd by once every 8 weeks(Q8W).
IBI302Biological
8 mg IBI302 will be administered by intraitreal injection into the study eye at intervals as specified in the study protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from baseline in Best corrected visual acuity ( BCVA ) in the study eye.Time frame: At week 44, 48, 52
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai General Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.